Enrique Carrazana
Director/Board Member at Hawaii Biotech, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Scott Braunstein | M | 60 | 6 years | |
| Dick L. Sherman | M | 76 |
Hawaii Biotech, Inc.
 Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| Craig Charles Chambliss | M | - |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 17 years |
| David Hale | M | 75 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 17 years |
| Todd Levine | M | - |
Cnd Life Sciences, Inc.
 Cnd Life Sciences, Inc. Medical/Nursing ServicesHealth Services Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello. | - |
| Steven Pfanstiel | M | 51 | 3 years | |
| Martha Manning | F | 69 | 4 years | |
| Sara Nochur | M | 63 | 3 years | |
| Christopher Gibbons | M | - |
Cnd Life Sciences, Inc.
Cnd Life Sciences, Inc. Medical/Nursing ServicesHealth Services Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello. | - |
| Charles Austin | M | 68 | 4 years | |
| Roy Freeman | M | 72 |
Cnd Life Sciences, Inc.
Cnd Life Sciences, Inc. Medical/Nursing ServicesHealth Services Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello. | - |
| Brittany Bradrick | F | 54 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 3 years |
| Vasant Narasimhan | M | 48 | 19 years | |
| Laurence Knutson | M | - |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| Samir Shah | M | 63 | 20 years | |
| Richard Morello | M | - |
Cnd Life Sciences, Inc.
Cnd Life Sciences, Inc. Medical/Nursing ServicesHealth Services Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello. | - |
| Stephen H. Jenner | M | 56 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 5 years |
| Kevin Kaijun Li | M | - |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | - |
| Elan Ezickson | M | 60 | 5 years | |
| Priyanka Belawat | M | 45 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | - |
| Seth Fischer | M | 68 | 8 years | |
| Peter Harris | M | - |
Cnd Life Sciences, Inc.
Cnd Life Sciences, Inc. Medical/Nursing ServicesHealth Services Cnd Life Sciences, Inc. is a company based in an undisclosed location that aims to transform the diagnosis and treatment of neurodegenerative diseases. The company is based in Scottsdale, AZ. The company operates a CLIA-certified and CAP-accredited laboratory and has launched the Syn-One test, the world's first commercially available test that detects and visualizes phosphorylated alpha-synuclein in cutaneous nerves with high accuracy to aid the diagnosis of Parkinson's disease and related disorders. Cnd Life Sciences has scientific collaborations with biopharmaceutical companies and has been awarded three NIH SBIR grants to advance the clinical utility of the Syn-One test. The company allows clinicians to access objective pathological insights on diseases that are often difficult to diagnose and apply those insights to generate better outcomes for patients. The company was founded in 2017 by Todd Dylan Levine, Christopher Gibbons, Roy Freeman, and the CEO is Richard J. Morello. | - |
| Christy Shafer | F | 48 | 4 years | |
| Barbara McNeil | M | 83 |
Harvard Medical School
| 41 years |
| Thomas Lyons | M | - | 6 years | |
| Joseph Hulihan | M | 68 | 5 years | |
| Michael C. Gibson | M | - |
Harvard Medical School
| 37 years |
| Debra R. Guerin Beresini | F | - |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| Jennifer Murata | F | - |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| George Church | M | 69 |
Harvard Medical School
| 38 years |
| Mark Bogart | M | - |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| David E. Clements | M | - |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | 37 years |
| Robert J. Robinson | M | - |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| Thomas Liquard | M | 51 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 7 years |
| Huai Zheng Peng | M | 62 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | - |
| Linda Armstrong | M | 61 | 17 years | |
| Steve Cartt | M | 61 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 4 years |
| David Smith | M | 64 |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA. | 3 years |
| Michele L. Yelmene | F | 60 |
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | - |
| Harry Werner Kirsch | M | 59 | 21 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edward Smith | M | 53 | 8 years | |
| Christopher Michael Cashman | M | 67 | 8 years | |
| Joseph Jimenez | M | 64 | 11 years | |
| Wendelin Wiedeking | M | 72 | 11 years | |
| Robert Morales | M | 57 | 7 years | |
| Ronen Tamir | M | 57 | - | |
| Ulrich Lehner | M | 78 | 13 years | |
| Andreas von Planta | M | 68 | - | |
| Lisa M. Caperelli | F | - | 6 years | |
| Michael Dougherty | M | 66 | 5 years | |
| Thomas Wellauer | M | 69 | - | |
| Juan Andres | M | 59 | 12 years | |
| Dirk van de Put | M | 63 | 1 years | |
| Peter Maag | M | 57 | 5 years | |
| Gail Farfel | M | 60 | 3 years | |
| Sasha Ellis | F | - | - | |
| Gary Sutton | M | - | 13 years | |
| Jürgen Brokatzky-Geiger | M | 72 | 14 years | |
| Anand Mehra | M | 48 | 9 years | |
| William Brody | M | 80 | - | |
| Ann Marie Fudge | F | 72 | - | |
| Srikant T. Madhav Datar | M | 70 | 18 years | |
| Mun Tak Yang | F | 70 | - | |
| Jay Shepard | M | 66 | - | |
| Stephen Bloch | M | 62 | 11 years | |
| Hans Jörg Reinhardt | M | 68 | 28 years | |
| Marc Semigran | M | 67 |
Harvard Medical School
| 5 years |
| Diane E. Sugrue | F | - | 9 years | |
| Gina Massa Mias | F | - | - | |
| Lishan Aklog | M | 58 |
Harvard Medical School
| 4 years |
| Lionel Ivashkiv | M | - |
Harvard Medical School
| 3 years |
| Thomas Werlen | M | - | 5 years | |
| Michael E. Greenberg | M | 69 |
Harvard Medical School
| - |
| William George | M | 81 | 10 years | |
| Nadia Dac | F | 54 | 4 years | |
| James Wassil | M | 54 | 7 years | |
| Frank Palantoni | M | 66 | 6 years | |
| Sabrina Comic Savic | F | - | 12 years | |
| David Tancredi | M | - |
Harvard Medical School
| 7 years |
| Marshall E. Reese | M | 78 | 5 years | |
| Liu Hui | M | 51 | 6 years | |
| Gilad S. Gordon | M | - |
Harvard Medical School
| 3 years |
| Beth Calitri | F | - | 8 years | |
| Paolo Baroldi | M | 73 | 4 years | |
| David Liu | M | 73 |
Harvard Medical School
| 10 years |
| Ian Garland | M | 59 | - | |
| Mihael Polymeropoulos | M | 64 | 5 years | |
| Mark W. Frohlich | M | 62 |
Harvard Medical School
| 3 years |
| Cornelia W. LeMaitre | F | 88 |
Harvard Medical School
| 7 years |
| James New | M | 70 | 2 years | |
| Mario R. Ehlers | M | 65 |
Harvard Medical School
| 5 years |
| Paul Herrling | M | 78 | - | |
| John Yu | M | 60 |
Harvard Medical School
| 3 years |
| Jeffrey Kang | M | - |
Harvard Medical School
| 10 years |
| Thomas Ebeling | M | 65 | 7 years | |
| Vincent Ippolito | M | 65 | 17 years | |
| Ravi Anand | M | 67 | 4 years | |
| Fredrik Ollila | M | - | - | |
| Matthew Sherman | M | 68 |
Harvard Medical School
| 18 years |
| Gilbert Thomas | M | - |
Harvard Medical School
| 5 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 60 | 60.00% |
| Switzerland | 40 | 40.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Enrique Carrazana
- Personal Network
